Novartis Pharmaceuticals and Health Canada inform health care professionals and the public about stronger safety recommendations regarding first-dose cardiovascular monitoring of Gilenya (fingolimod) and its use in patients with pre-existing cardiovascular conditions. There have been reports of isolated delayed-onset cardiovascular events, including transient asystole and unexplained death within 24 hours of the first dose of Gilenya. No deaths have been reported in Canada; however, 54 Canadian case reports of serious cardiovascular adverse events have been reported between March 09, 2011, and January 31, 2012 , where the majority of these cases (e.g., bradycardia, hypertension, hypotension, dizziness, malaise, palpitations) have occurred within the first 6 hours of the first dose. The updated product monograph advises that an electrocardiogram be performed and blood pressure measured prior to and 6 hours after the first dose of Gilenya. Further, all patients should be monitored for signs and symptoms of bradyarrhythmia with hourly pulse and blood pressure measurement for at least 6 hours after the first dose and appropriate measures taken if heartrelated side effects occur. If serious heart-related adverse effects occur at the end of the 6-hour observation period, patients may require monitoring for a longer period. Please refer to the product monograph for further information, including a description of patient groups in which Gilenya should not be used. Sanofi Pasteur and Health Canada inform health care professionals and the public that a voluntary recall of several Typhim Vi (Vi polysaccharide typhoid vaccine) batches has been initiated due to potentially lower-thanexpected antigen content that may not provide the intended protection against the disease. For patients who may have received a Typhim Vi vaccination from these batches, the company does not recommend revaccination earlier than otherwise indicated. There are no tests available that can easily evaluate the level of anti-Vi serum antibodies in patients. Syringes and 20-dose vials of the following batches are impacted: G1122-1, G1557-1, G0182-2 and H0176-1. Continue to remind patients to avoid potentially contaminated food and drink, as vaccination against typhoid fever does not preclude this recommendation.
Inlyta (axitinib 1 mg and 5 mg tablets by Pfizer) is an oral kinase inhibitor approved for the treatment of patients with metastatic renal cell carcinoma of clear cell histology after failure of prior systemic therapy with either a cytokine or the VEGFR-TK1, sunitinib. Inlyta should be prescribed by a qualified health care professional who is experienced in the use of antineoplastic therapy. Clinically significant adverse events associated with Inlyta are hypertension, arterial thromboembolism, hemorrhage, gastrointestinal perforation, reversible posterior leukoencephalopathy syndrome and associated deaths. Inlyta is not recommended in combination with strong inhibitors and inducers of CYP3A4. The recommended starting dose is 5 mg twice daily taken orally with or without food and swallowed whole with a glass of water. Patients who tolerate the starting dose with no adverse reactions (>Grade 2 according to Common Toxicity Adverse Event Criteria) for 2 consecutive weeks, are normotensive and are not receiving blood-pressure-lowering agents, may have their dose increased to 7 mg twice daily. The maximum dose is 10 mg twice daily. The starting dose is decreased by approximately half in patients with moderate hepatic impairment. Inlyta should not be used in patients with severe hepatic impairment, as it has not been studied in this population. Review and assess patients' current medication(s) for interactions prior to initiation of Inlyta. 
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